Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHERGAIN-2: Chemotherapy-free pCR-guided strategy with subcutaneous trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer
2020-003205-66Phase 2Active
- Sponsor
- MEDSIR
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of trastuzumab emtansine, trastuzumab and pertuzumab in breast cancer, sponsored by MEDSIR. Primary endpoint: Primary efficacy endpoint. Started Jul 2021; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-003205-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003205-66.